We’re excited to share two major milestones from our SOSV portfolio company Cayuga, which is developing a novel therapeutic approach to address life-threatening hemorrhage. Hemorrhage causes nearly 2 million deaths each year worldwide, and remains a leading cause of death in surgery, trauma, childbirth, and among patients on blood thinners. Yet current treatments often fail […]

A new hope for patients with genetic kidney diseases. Helex, an SOSV portfolio company and graduate of the IndieBio startup development program, which is developing a new class of targeted medicines for genetic kidney disorders, announced its $3.5M Seed round, led by pi Ventures, with participation from Bluehill Capital, SOSV, and others. Helex is tackling […]

We’re thrilled to announce that Samphire Neuroscience, a graduate of our HAX hard tech startup development program, has secured $5 million Seed round led by Inventure VC with participation from Fortify Ventures. Earlier this year, the company launched Nettle—a CE-certified, non-hormonal neurotechnology device designed to relieve mental and physical symptoms tied to menstruation. Using gentle transcranial […]

SOSV is hosting a completely free VC-Founder virtual matchmaking event focused on Health Tech. The 1:1 meetings will be taking place online between Monday, June 23 and Friday, June 27. 800+ startups | 400+ investors | 1 week of 1:1 meetings | Virtual | FreeThe largest event of its kind! Event Description The event is […]

San Francisco Climate Week is around the corner, and the IndieBio team is gearing up for a dynamic week of thought-provoking conversations with leaders at the forefront of climate tech. We’re excited to invite you to three incredible events focused on the intersection of innovation, investment, and impact. Details below: 🤖 Breakthroughs in AI x […]

Welcome to the Biomanufacturing Matchup Event, where biology meets bold ambition. EXPECTED > 200 startups | 200 investors | 1 week of virtual meetings | FreeUPDATE (APR.14) > There are already 250+ startups and 250+ investors registered! From sustainable jet fuel to protein production, from next-gen pharmaceuticals to high-performance biomaterials—there are few limits to what […]

SOSV’s IndieBio NY just held a demo day at its offices in Manhattan. Fifteen spectacular deep tech founders tackling human and planetary health took the stage in front of a packed audience of investors. The IndieBio NY team made this terrific video to kick off the event and introduce the main deep tech themes of […]

Introducing Deborah Zajac, SOSV’s newest general partner and member of the IndieBio NY team.

Zurich-based Oxyle recently raised a $16M seed round led by 360 Ventures with participation from Axeleo Capital, Founderful and SOSV, according to a report in Forbes. Water supplies around the world are contaminated with “Forever Chemicals,” or the 10,000 perfluoroalkyl and polyfluoroalkyl substances known by the acronym PFAS. They are linked to a sharp increases […]

Rybodyn, Inc. is making waves in biotech with its groundbreaking discovery of a cryptic human proteome and a $4 million pre-seed funding round.